Drug Profile

MUC1 infected dendritic cells induced cytotoxic T lymphocyte therapy - Beijing Doing Biomedical

Latest Information Update: 06 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Doing Biomedical
Class Antineoplastics; Dendritic cell vaccines; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Sep 2023 Discontinued - Preclinical for Gastric cancer (Late-stage disease) in China (IV)
28 Jul 2019 No recent reports of development identified for preclinical development in Gastric-cancer(Late-stage disease) in China (IV, Infusion)
01 Jun 2015 Preclinical trials in Gastric cancer (Late-stage disease) in China (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com